Literature DB >> 12358908

Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome.

J Joseph Melenhorst1, Rhoda Eniafe, Dean Follmann, Ryo Nakamura, Martha Kirby, A John Barrett.   

Abstract

We studied 18 patients with myelodysplastic syndrome (MDS), measuring clonality and T-cell receptor Vbeta (TCRBV) expression of CD4 and CD8 T cells by polymerase chain reaction and by flow cytometric analysis of TCRBV families. The CD4 and CD8 T-cell repertoire in most MDS patients is characterized by an abnormal TCRBV-restricted expansion of T cells in CD4 and CD8 cells, and increased expression of the CD8 effector marker CD57 of multiple TCRBV in CD8 cells. Clonality analysis of CD4 and CD8 cells showed that seven of 10 patients analysed had a major clone in the CD8 cells but not in CD4 cells. Furthermore, in one patient we found that both the CD57- and CD57+ fraction contained the clone (which was absent from the TCRBV-negative fraction). These data suggest that, in MDS, multiple T-cell expansions can be found in both helper and cytotoxic T cells, and that, in the CD8 cells, T cells functionally differentiate in vivo from memory to effector T cells. Together, these data support the hypothesis of the involvement of T cells in the pathogenesis of MDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358908     DOI: 10.1046/j.1365-2141.2002.03802.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 2.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 3.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.

Authors:  Jeffrey L Lew; Joshua L Fenderson; Mark G Carmichael
Journal:  Hawaii J Med Public Health       Date:  2017-11

5.  A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Authors:  Chi-Yuan Yao; Ching-Hsuan Chen; Huai-Hsuan Huang; Hsin-An Hou; Chien-Chin Lin; Mei-Hsuan Tseng; Chein-Jun Kao; Tzu-Pin Lu; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Adv       Date:  2017-08-16

6.  Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among HIV-1 infected individuals before and after antiretroviral therapy.

Authors:  Carmem Beatriz Wagner Giacoia-Gripp; Ivan Neves; Maria Clara Galhardo; Mariza Gonçalves Morgado
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

7.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

Review 8.  Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.

Authors:  Ankur R Parikh; Matthew J Olnes; A John Barrett
Journal:  Semin Hematol       Date:  2012-10       Impact factor: 3.851

9.  Myelodysplasia and Good syndrome. A case report.

Authors:  M Di Renzo; A L Pasqui; L Voltolini; G Gotti; G Pompella; A Auteri
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

10.  Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction.

Authors:  Michael L Chen; T Daniel Logan; Maryann L Hochberg; Suresh G Shelat; Xiang Yu; Gregory E Wilding; Wei Tan; Gregory C Kujoth; Tomas A Prolla; Mary A Selak; Mondira Kundu; Martin Carroll; James E Thompson
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.